Article Details
Retrieved on: 2021-06-23 13:40:40
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Following the discontinuation of Sangamo's SB-FIX and Takeda's TAK-748, Uniqure's main rivals are Pfizer/Roche's fidanacogene elaparvovec and ...
Article found on: www.evaluate.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here